2023 article

Establishment of a consensus protocol to explore the brain pathobiome in patients with mild cognitive impairment and Alzheimer's disease Research outline and call for collaboration

Lathe, R., Schultek, N. M., Balin, B. J., Ehrlich, G. D., Auber, L. A., Perry, G., … Tanzi, R. E. (2023, June 7). ALZHEIMERS & DEMENTIA.

By: R. Lathe*, N. Schultek, B. Balin*, G. Ehrlich*, L. Auber, G. Perry*, E. Breitschwerdt n, D. Corry* ...

co-author countries: Switzerland 🇨🇭 United Kingdom of Great Britain and Northern Ireland 🇬🇧 United States of America 🇺🇸
author keywords: Alzheimer's disease; antimicrobial; antiviral; bioinformatics; blood; cerebrospinal fluid; collaboration; dementia; diagnosis; methodology; microbiome; mild cognitive impairment; olfactory neuroepithelium; pathobiome; polymerase chain reaction; protocol; sequencing
Source: Web Of Science
Added: July 3, 2023

Microbial infections of the brain can lead to dementia, and for many decades microbial infections have been implicated in Alzheimer's disease (AD) pathology. However, a causal role for infection in AD remains contentious, and the lack of standardized detection methodologies has led to inconsistent detection/identification of microbes in AD brains. There is a need for a consensus methodology; the Alzheimer's Pathobiome Initiative aims to perform comparative molecular analyses of microbes in post mortem brains versus cerebrospinal fluid, blood, olfactory neuroepithelium, oral/nasopharyngeal tissue, bronchoalveolar, urinary, and gut/stool samples. Diverse extraction methodologies, polymerase chain reaction and sequencing techniques, and bioinformatic tools will be evaluated, in addition to direct microbial culture and metabolomic techniques. The goal is to provide a roadmap for detecting infectious agents in patients with mild cognitive impairment or AD. Positive findings would then prompt tailoring of antimicrobial treatments that might attenuate or remit mounting clinical deficits in a subset of patients.